This Weekly’s Hot Topics
- MolDX: ResponseDX Tissue of Origin – R2, coverage article has been revised. (Noridian News)
- ANCO President, Daniel P. Mirda, M.D., chosen as one of ASCO’s Advocacy Champions (ANCO News)
- Last week to submit comments to CMS regarding the 340B Drug Pricing Program (CMS News)
One of the bills in the California legislature designed to address high prescription drug costs takes aim at the middlemen who negotiate pharmaceutical prices by bringing them under the state’s regulatory purview. Pharmacy benefit managers represented by the trade group The Pharmaceutical Care Management Association, are the go-betweens who negotiate drug prices with manufacturers on behalf of health insurers. For more information click here and go to California News.
AB 205 (Wood): Medi-Cal: Medi-Cal managed care plans. This bill would require the Department of Health Care Services to make several changes to the operation of the Medi-Cal managed care program, to conform to new federal requirements. Patient advocacy groups strongly support the access to care standards included in the bill. For more information click here and go to Noridian News.
Limited drug access, power outages and floodwater injuries are challenges the residents of Houston will have to face right away. Are you ready for the natural disasters facing your community through earthquake, fire and flood? Not only do we have emergency disasters in California, but every community across the United States have such emergencies!. For more information click here and go to MOASC News.
The Medicare appeals backlog is significant and has been increasing in recent years. In an effort to reduce the backlog, HHS has issued a final rule, which includes an assortment of initiatives. There are steps providers can take to reduce the risk and/or negative outcomes of an SMRC review, including using trigger language and ensuring time stamps. For more information click here and go to CMS News.
To view the complete California Oncology Weekly Newsletter, click on the date below.